ABT
Abbott Laboratories
ABT has the edge over NVO overall on the model score.
NVO
Novo Nordisk A/S
NVO has slightly lower modeled downside risk, despite its lower overall score.
ABT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Healthy | |
| Under pressure |
ABT's revenue and cash flow are currently healthy, and its profitability is stable, but its balance sheet is under pressure.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
ABT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $107 | — |
| Cheap | 22x | $58.67 | -45% |
| Fair | 33x | $88.57 | -17% |
| Current | 40x | $107 | — |
| Expensive | 45x | $121 | +13% |
Historical ranges are pointers, not guarantees.
ABT's PE is in its expensive range at 40x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over ABT in the historical PE scenario, which offers more potential upside but is not a forecast.
ABT Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Moderate | |
| High |
ABT has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
ABT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.84 | +118% |
| Q3 2026 | $2.68 | -66% |
| Q2 2026 | $3.09 | -61% |
| Q1 2026 | $3.57 | -54% |
| Q4 2025 | $3.72 | -51% |
| Q3 2025 | $7.97 | +142% |
| Q2 2025 | $7.97 | +151% |
| Q1 2025 | $7.70 | +140% |
| Q4 2024 | $7.64 | +134% |
ABT's earnings per share have fallen from their peak: $2.68 over the past year, against $7.97 in mid-2025.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
ABT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $13B | +14% |
| Q2 2026 | $12.6B | +13% |
| Q1 2026 | $11.2B | +7.8% |
| Q4 2025 | $11.5B | +4.4% |
| Q3 2025 | $11.4B | +6.9% |
| Q2 2025 | $11.1B | +7.4% |
| Q1 2025 | $10.4B | +4% |
| Q4 2024 | $11B | +7.2% |
ABT's revenue has grown year over year for 12 quarters in a row: $13B last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 10% | -7.7 points |
| Q2 2026 | 13% | -5 points |
| Q1 2026 | 12% | -4.3 points |
| Q4 2025 | 20% | +2.2 points |
| Q3 2025 | 18% | +0.6 points |
| Q2 2025 | 18% | +2.3 points |
| Q1 2025 | 16% | +2.4 points |
| Q4 2024 | 17% | 0 points |
ABT's operating margin was 10% last quarter, down 7.7 points from the same quarter a year ago, near the bottom of its range since 2019.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over ABT on profitability, with a higher operating margin.
ABT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.2B | -47% |
| Q2 2026 | $2B | +29% |
| Q1 2026 | $916M | -1.8% |
| Q4 2025 | $2.6B | +22% |
| Q3 2025 | $2.3B | +6.6% |
| Q2 2025 | $1.5B | +8.3% |
| Q1 2025 | $933M | +49% |
| Q4 2024 | $2.1B | -5.9% |
ABT's free cash flow has been positive every quarter for seven years: $6.8B over the past year, down 2.3% from the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
ABT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -5.1M shares |
| 1 year | -0.7% | -11.5M shares |
| 3 years | -0.6% | -10.4M shares |
| 5 years | -2.9% | -51.1M shares |
| Available history | -2.4% | -43.1M shares |
ABT has the edge over NVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $11M |
| Q2 2026 | $1B |
| Q1 2026 | $180M |
| Q4 2025 | $302M |
| Q3 2025 | $305M |
| Q2 2025 | $6M |
| Q1 2025 | $280M |
| Q4 2024 | $315M |
ABT spent $1.5B buying back its own shares over the past year, up 70% from the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
ABT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.6x | Moderate |
| Q2 2026 | 2.6x | Moderate |
| Q1 2026 | 2.5x | Moderate |
| Q4 2025 | 0.4x | Very low |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 0.6x | Very low |
| Q1 2025 | 0.7x | Very low |
| Q4 2024 | 0.7x | Very low |
ABT's net debt is about 2.6 years of its operating earnings (EBITDA), up from less than a year a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over ABT on leverage, with a lower net debt burden relative to earnings.
ABT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.0 | Neutral |
| Stochastic | 57.1 | Neutral |
ABT's weekly RSI is 54 (neutral) and its Stochastic is 57 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
ABT PE vs Healthcare Sector
| Metric | ABT | Sector median | Relative |
|---|---|---|---|
| PE | 40x | 26x | 55% above |
| PE % | 81 | 29 | 52 pts above |
ABT is trading at 40x earnings, a 55% premium to the Healthcare sector's median of 26x.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over ABT on valuation relative to its sector.
ABT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $103.8 | 3.3% above |
| 20 week MA | $104.5 | 2.6% above |
| 50 week MA | $104.9 | 2.3% above |
| 100 week MA | $117.0 | 8.4% below |
| 200 week MA | $112.4 | 4.6% below |
ABT has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
ABT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $87.4 | $108.4 | +24% |
| 2021 | $108.4 | $139.2 | +28% |
| 2022 | $139.2 | $108.2 | -22% |
| 2023 | $108.2 | $110.1 | +1.7% |
| 2024 | $110.1 | $115.0 | +4.5% |
| 2025 | $115.0 | $124.8 | +8.6% |
| 2026 YTD | $124.8 | $107.3 | -14% |
ABT has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.